PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Exclusion Criteria

• •Has not recovered (recovery is defined as National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE version (v)4.03\] grade =\< 1) from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting the inclusion requirements stated in the inclusion criterion
• •Prior treatment with a PARP inhibitor
• •Prior allergic reaction or severe intolerance to either irinotecan or temozolomide
• •History of central nervous system (CNS) metastasis that are untreated or not stable
• •Any antitumor systemic cytotoxic therapies within 28 days prior to enrollment (6 weeks for nitrosoureas or mitomycin-C); prior high-dose chemotherapy with bone marrow or stem cell transplant is excluded
• •Is known to have human immunodeficiency virus (HIV) or has active hepatitis C virus (HCV), or active hepatitis B virus (HBV)
• •Has had major surgery within 28 days prior to enrollment
• •Active gastrointestinal tract disease with malabsorption syndrome
• •Requirement for IV alimentation
• •Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
• •Symptomatic congestive heart failure (New York Heart Association \> class II), unstable angina, or unstable cardiac arrhythmia requiring medication (atrial fibrillation is permitted)
• •Use of any investigational product or investigational medical device within 28 days prior to enrollment
• •Concurrent disease or condition that would interfere with study participation or safety, such as:
• •* Active, clinically significant infection requiring the use of parenteral anti-microbial agents, or grade \> 2 by NCI CTCAE (v 4.03) within 14 days prior to enrollment
• •* Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders
• •* Non-healing wound, ulcer, or bone fracture
• •* Bone marrow disorder including myelodysplasia